Teva loses Copaxone patent dispute case to Mylan in UK
Synthon is the partner of the US-based Mylan for the development and supply of its Glatiramer Acetate Injection 40mg/mL product across Europe. The 3-times-a-week injection is the substitutable
Novartis has begun construction on its new 46,000ft² radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research.
"This study demonstrates the feasibility of using genome-wide molecular tests to guide treatment in recurrent glioblastoma," according to a scientific paper published today in Clinical Cancer Research, a journal
Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while MacroGenics retains the right to develop its pipeline assets in combination